Funded by: Instituto de Salud Carlos III and European Union Next Generation EU / PRTR
Period: 01/01/2022 – 31/12/2024
Partners: Fundació Privada per a la Recerca i la Docència Sant Joan de Déu (FSJD) (Spain), Nehir Biyoteknoloji Ltd. (NehitBT) (Turkey), Palacký University Olomouc (UP) (Czech Republic)
GLEBioassay aims to develop a multiplexed point of care nanobiosensing platform to monitor the efficacy of the naxitamab-based immunotherapy in neuroblastoma. Naxitamab is a humanized anti-GD2 monoclonal antibody elicitor of the complement dependent toxicity and the antibody dependent cellular cytotoxicity. It is less immunogenic and more effective than previous chimeric antibody-based immunotherapies and FDA has recently approved its use against refractory/relapsed high-risk neuroblastoma. Some patients under treatment can develop human anti-human antibodies (HAHAs), thus provoking the deferment or suspension of the therapy. Conversely, this treatment induces in some patients a vaccine effect, when they start producing their own anti-GD2 antibodies. Currently, there is no standardized and accurate method to determine naxitamab, HAHAs and anti-GD2 in patients undergoing therapy. In this context, the main goal of the project is to develop a novel platform to monitor the pharmacodynamics and pharmacokinetics of naxitamab in real samples, obtaining the results in one step.
GLEBioassay will bring an electrophoretical paper-based portable platform with an electrochemical readout for multiplexed immunosensing. In contrast to lateral flow systems where the sample runs by capillarity with optical detection; in our approach the mobility is driven by electrophoresis enabling a continuous flow, separating its components and cleaning the whole pad. Furthermore, we will use a fast stamping method of laser-scribed graphene nanofilms. This technique allows an electrochemical detection using antibodies tagged with electroactive nanoparticles with the advantage of a lower limit of detection and more accurate results.
Due to the versatility of the proposed platform, the outcome of the project can also be applied to different scenarios or other immunotherapies where a fast and efficient point of care biosensor is needed.